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Summary 
CDllc/CD18 (p150,95) is a/32 integrin expressed by myeloid, natural killer and certain lymphoid 
cells such as some cytotoxic T cell clones and B cell malignancies. We have studied the expression 
and function of CD11c on resting and activated  B lymphocytes. Flow cytometry, immuno- 
precipitation, and mRNA analyses showed that cell activation with phorbol esters or with a 
variety of stimuli such as Staphylococcus aureus or anti-/z antibodies in combination with cytokines 
induced de novo CDllc/CD18 cell surface expression on most B cells while CDllb expression 
was not affected. Functional analysis of CDllc/CD18 on B cells revealed that it plays a dual 
role. First, CDllc/CD18 is implicated in B cell proliferation, as demonstrated by the ability of 
several anti-CDllc monoclonal antibodies to trigger comitogenic signals; and second, the newly 
expressed CDllc/CD18 mediates B cell binding to fibrinogen. Our data conclusively demonstrate 
the role of CDllc/CD18  on both B cell activation and adhesion processes. 
T 
he integrin family is composed by at least 15 cell surface 
heterodimeric glycoproteins that function in cell-cell con- 
tacts and cell-extracellular  matrix interactions (reviewed in 
references 1-5). Although originally believed to participate 
only in adhesion processes, recent studies indicate that inte- 
grins are also involved in cell activation phenomena (6-15). 
Integrins have been divided in three subfamilies that can 
be distinguished by their common use of a unique/3 chain 
noncovalently associated with several distinct c~ chains, p150,95 
(CDllc/CD18),  together with LFA-1 (CDlla/CD18)  and 
Mac-1 (CDllb/CD18), belongs to the/32 integrin subfamily 
whose expression  is restricted to leukocytes.  While LFA-1 
is expressed on all leukocytes, Mac-1 and p150,95 are expressed 
mainly by granulocytes, monocytes and NK cells (16, 17). 
Moreover, CDllc/CD18 is present on dendritic cells (18, 19), 
certain cytotoxic T cell clones (20),  and some lymphocytes 
of the B cell lineage like those of the hairy cell leukemia 
(HCL) 1 (21). Coexpression of Mac-1 and p150,95 by some 
B cell chronic lymphocytic leukemias (B-CLL) has also been 
reported (22). CDllc/CD18 has been described participating 
in a number of adhesion phenomena such as binding to the 
1  Abbreviations used in this paper: Ab,  antibody; BCLL,  B  cell chronic 
lymphocytic leukemias; FG, Fibrinogen; HCL, hairy cell leukemia; SAC, 
Staphylococcus aureus Cowan I. 
iC3b or fibrinogen and attachment to endothelium (reviewed 
in reference 3). 
During activation, B cells undergo a number of changes 
on the expression of their different surface antigens (23-32). 
Since Mac-1 and p150,95 are expressed by certain transformed 
B cells, we explored whether these two integrins could be 
induced during in vitro activation of normal B cells. The data 
reported here demonstrate that  cell  surface  expression  of 
CDllc/CD18, but not CDllb/CD18, is induced during ac- 
tivation  of purified B  lymphocytes. The involvement of 
CDllc/CD18 on B cell activation is highlighted by the ca- 
pacity of CDllc mAbs to trigger comitogenic signals on B 
lymphocytes. In addition, the expression of CD11c/CD18 also 
confers flbrinogen binding ability to B cells. 
Materials and Methods 
Monoclonal Antibodies.  BU12  mAb (anti-CD19) was generously 
provided by Dr. Johnson (University of Birmingham, UK). 1F5 
mAb (anti-CD20) was  a  gift  from Dr.  Clark  (University of 
Washington, Seattle, WA). HB5 mAb (anti-CD21) was generously 
provided  by Dr. Cooper (La JoUa, CA). HC1/1 mAb (IgG1) directed 
to c~ chain of p150,95 was obtained in our laboratory (33). Other 
CDllc mAbs were kindly provided by Dr. Johnson (BU15 mAb, 
IgG1), Dr. Lanier (DNAX, Palo Alto, CA) (L29 mAb, IgG1), Dr. 
Pulford (University  of Oxford, UK) (KB23 and KB90 mAbs), and 
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(S-HCL 3 mAb, IgG2a). TS1/11 mAb directed to CD11a chain, 
TS1/18 mAb against the 82 integrin, and Bear 1 mAb directed 
to CD11b molecule  were previously  described (34, 35). TS2/18 mAb 
is directed  against the CD2 antigen. Anti-CD69 TP1/8, anti-CD45 
D3/9, and anti-CD49d (VLA-c~4) HP2/1 mAbs were obtained in 
our laboratory (36-38). F(ab')2 fragments of HC1/1  mAb were 
obtained upon pepsine treatment as described (39). 
Cells and Cell Cultures.  Tonsillar B cells were obtained from 
children 4-12 yr old undergoing routine tonsillectomy.  Mononuclear 
cells were isolated by Ficoll-Hypaque (Pharmacia Fine Chemicals, 
Uppsala, Sweden) centrifugation and enriched for B cells by roset- 
ting with 2-aminoethyl-isothiouronium bromide (AET) (Sigma 
Chemical Co., St. Louis, MO)-treated sheep erythrocytes (Bio- 
merieux, Marcy-12Etoile, France). The resulting B cell-enriched 
population was >95%  CD19 + and CD20 §  and <2% CDllb § 
and CD2 +. 
In some experiments, tonsillar B cells were separated over a Per- 
coll (Pharmacia  Fine Chemicals)  discontinous  gradient on five  bands 
that layered from medium to 45%, 45-55%,  55-65%,  65-75%, 
and 75-100%. Then, each fraction was activated and assayed for 
flow cytometry. 
Peripheral blood B cells were obtained from heparinized venous 
blood of normal voluntary donors. After Ficoll-Hypaque  centrifu- 
gation, peripheral mononuclear cells  were depleted  of  adherent cells 
by two steps of adherence incubation in plastic flasks  (Costar, Cam- 
bridge, MA) at 37~  and 5%  COs atmosphere for 2 h.  T cell 
depletion was accomplished  by removing  the cells that rosetted with 
AET-treated sheep erythrocytes  as described  above. Cells were grown 
in RPMI 1640 (Whittaker M.A. Bioproducts, Walkersville,  MD) 
supplemented with 10% FCS (Biochrom; Seromed, Berlin, Ger- 
many), 2 mM r-glutamine (Whittaker M.A. Bioproducts), 50 U/ml 
of penicillin, and 50/~g/ml of streptomicin (Whittaker M.A. Bin- 
products). This medium will be referred as complete medium. 
Reagents.  Human rlL-2 and rlFN-'y was a generous gift from 
Hoffman-La Roche, Inc. (Nutley, NJ). Human rib4 was kindly 
provided by Dr. J. de Vries (Unicet Labs., Dardilly, France) and 
human  ffNF-cr  by Labs. Andr6maco  (Madrid, Spain). PMA, 
phorbol 12,13 dibutyrate (PDB), and F(ab')s fragments of rabbit 
polyclonal  antibodies to human # chain were purchased from Sigma 
Chemical Co. Staphylococcus  aureus strain Cowan I (SAC) (Pansorbin) 
was  acquired to Calbiochem-Behring Corp.  (San Diego,  CA). 
Cytokines are used at the following doses: rIL-2, 50 U/m1; rIL-4, 
600 U/m1; rTNF-ot, 100 rig/m1; rIFN-% 200 U/ml. SAC was used 
at a 1/104 (vol/vol) dilution.  Anti-# antibodies were coated to 
plastic plates at 50 lzg/ml in PBS, pH 8.0, overnight at 4~ 
Flow Cytometry Analysis.  1.5-2 x  10  s cells were incubated 
with 100 #1 hybridoma culture supernatants for 30 rain at 4~ 
After two washes with cold PBS, the cells  were stained with a goat 
anti-mouse  F(ab')s fragment FITC (Dakopatts, Glostrup, Den- 
mark) followed  by two additional washes with cold PBS. CeU im- 
munofluorescence  was analyzed  by flow cytometry using a EPICS- 
C (Coulter Immunology, Hialeah, FL). Fluoresceined  rnicrospheres 
of different intensities were analyzed in both log and linear scale, 
and a standard conversion scale was constructed. Cell fluorescence 
data were collected on the log scale and converted to the linear 
scale for a quantitative estimation. Specific relative linear fluores- 
cence was obtained by subtracting background linear fluorescence 
produced by the negative  control myeloma  P3X63. The percentage 
of positive cells was calculated by subtracting the percentage of 
control X63 from that obtained with every specific marker. 
~2sI Radiolabelin$ Immunoprecipitation, and Electrophoresis.  Ton- 
sillar B lymphocytes and granulocytes were radioiodinated with 
tetrachloro-diphenil-glycoluril  (Iodogen; Sigma Chemical  Co.) and 
1 mCi of 12sI (DuPont Co., Wilmington, DE) each 2  x  107 cells. 
Ceils were lysed  in a buffer  lysis  containing 1% NP-40 (Sigma  Chem- 
ical Co.), 10 mM Tris-HC1, pH 7.4, 0.15 M NaC1, 1% BSA, 1 
mM PMSF (Sigma Chemical Co.), 1 mM EDTA, and 50 mM NaF. 
Equal amounts of input radioactivity  of 12sI-hbeled cell lysates  (106 
cpm/condition) were incubated with 100 #1 ofmAb culture super- 
natants. Immunecomplexes  were isolated by incubation with 100 
#1 of 187.1 anti-mouse K  chain mAb followed  by incubation with 
30 #1 of protein A from S. aureus coupled to Sepharose (CL-4B; 
Pharmacia Fine Chemicals). Immunoprecipitates were processed 
as described elsewhere. Samples were resolved in 7% SDS-PAGE 
gels and autoradiographed. 
RNA Blot Hybridization.  Total  RNA from tonsillar B cells and 
the U937 cell line was prepared by the  guanidinium  thiocya- 
nate/cesinm chloride method.  10/zg/lane was loaded on formal- 
dehyde-agarose gds, subjected to electrophoresis, and transferred 
to nitrocellulose filters (Bio-Rad Laboratories, Richmond,  CA). 
Blots were hybridized with ~sP-labeled 0.8-kb PstI CDllc probe 
(40) and a 1-kb EcoRI CD18 fragment (41). 
Proliferation Assays.  Purified  tonsillar B lymphocytes at 1.5  x 
106 cells/ml were added in  100/~1 of complete medium to flat- 
bottomed 96-well culture plates (Costar). The different  stimuli and 
mAbs were added each in 10/~1 and wells were completed with 
RPMI 1640-10% FCS to reach 200 #1. Plates were incubated for 
72 h at 37~  in a 5%  COs atmosphere. In proliferation assays 
with crosslinked mAb, wells were coated with purified mAb at 
different concentrations. After overnight incubation, plates were 
gently washed  with RPMI 1640 and cells were added. Cell prolifer- 
ation  was  estimated by  [SH]TdR (DuPont  Co.)  incorporation 
during the last 18 h of culture. Cells were harvested in a cell har- 
vester (Skatron, Lier, Norway), and the radioactivity  was measured 
in a liquid scintillation 3 counter (Kontron, Zurich, Switzerland). 
Cell Attachment Assays.  Fibrinogen and type I collagen were 
purchased from Sigma Chemical Co. A 38-kD proteolytic fibro- 
nectin fragment was kindly provided  by Dr. A. Garda-Pardo (Centro 
Investigaciones Biol6gicas, Madrid). 96-well microtiter  EIA II 
Linbro plate (Flow Laboratories, Inc., McLean, VA) were coated 
overnight at 4~  with 100 #1 of different proteins dissolved in 
CO3HNa (0.1 M) at 20 #g/ml and then saturated with RPMI 
1640-1% HSA for 2 h at 37~  Thereafter, plates were washed 
gently with medium and  1.5  x  105 cells/well in  100 ~1 were 
added and incubated for 30 rain at 37~  After incubation, plates 
were washed three times and examined in an inverted microscope 
by at least two independent observers. Each condition was per- 
formed on duplicate. Cells were counted from at least three fields 
within each well. The number of cells counted in a nonwashed 
well was referred as input cells. In inhibition assays, cells were in- 
cubated for 30 rain at 4~  with the different mAbs and then added 
to wells. 
Results 
Induction of CDllc Expression after B Cell Activation.  Flow 
cytometry was used to study the ceU surface expression pat- 
tern of the/~2 integrin family during B ceU activation. As 
previously described,  nonactivated B cells highly expressed 
CDlla and CD18, whereas no significant expression of CDllb 
(<1%) or CDllc (<5%) was detected (Fig.  1). To ascertain 
whether B cell activation could alter the expression  of/~2 
integrins, purified tonsillar B cells were treated with PMA. 
Phorbol ester treatment induced an increase in CD11a and 
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Figure 1.  Expression  of B2 integrins 
on nonactivated and activated tonsillar 
B cells. Immunofluorescence  flow cyto- 
merry analysis was performed on ton- 
sillar B lymphocytes  either nonactivated 
or cultured for several  days in the pres- 
ence of PMA (5 ng/ml). Cells were la- 
beled with TS1/11 mAb (CDlla), Bear 
1 mAb (CDllb), HC1/1 mAb (CDllc), 
or TS1/18 mAb (CD18) (solid lines), and 
with the negative control X63 (dotted 
line). In a second step, the cells were 
stained with a goat anti-mouse IgG 
FITC.  Cell immunofluorescence was 
analyzed in an EPICS-C. x-axis, log 
fluorescence  intensity; y-axis, frequency. 
CD18 expression  without significant  changes in the percentage 
of positive cells.  On the contrary,  PMA  elicited a  gradual 
induction in the expression of CDllc  and,  at day 3,  most 
B cells became CDllc + . The percentage of CDllc + cells re- 
mained constant at days 4 and 5 (Fig. 1, and data not shown). 
No concomitant increase of CDllb expression was detected 
under the same conditions. This selective CDllc induction 
was not restricted to a particular tonsillar B cell subpopula- 
tion as shown by PercoU gradient separation (see Materials 
and Methods), and was also observed on purified peripheral 
blood B  cells (data not  shown). 
Next, we investigated whether the PMA-induced CD11c 
expression could be altered by other stimuli each as the poly- 
donal activator SAC, rlL,2, rib4, rlFN-3,, rTNF-ol, or anti-# 
antibodies (Ab).  PMA-induction  of CDllc/CD18  was sig- 
nificantly enhanced by SAC, rTNF-ol, or polyclonal anti-# 
Ab (data not shown). Similarly, CDllc expression could also 
be obtained after treatment with more "physiological" B cell 
activation agents: SAC or anti-# Ab combined with cytokines 
were able to induce CDllc expression, although to a lesser 
extent than phorbol esters  (Table 1). 
The induction of CDllc expression was studied at the bio- 
chemical level by immunoprecipitation from both activated 
and nonactivated tonsillar B cell lysates with mAbs against 
the different members of the B2 integrin family (Fig. 2). While 
only CDlla and CD18 glycoproteins were precipitated from 
nonactivated B cells (Fig. 2 A), immunoprecipitation from 
3-d phorbol ester-activated tonsillar B lymphocytes revealed 
the presence of CDllc/CD18,  with its corresponding poly- 
peptides of 150 and 95 kD (Fig. 2 B), thus confirming the 
cell surface expression of this heterodimer on activated B cells. 
On neutrophils, activation is followed by a rapid increase 
in the cell surface expression of Mac-1  and CDllc,  due to 
Table  1.  Induction of CDllc  on 3-d-activated Tonsiltar 
B  Cells  by SAC,  anti-IgM,  and Cytokines 
Percent of  Specific relative 
Stimulus  positive cells  fluorescence 
Control  2  1 
rlL-2  1  3 
rlL-4  16  10 
rTNF-c~  3  2 
rlFN-3'  2  1 
SAC  18  14 
SAC  +  rlL-2  22  15 
SAC  +  rlL-4  33  19 
SAC  +  rTNF-a  31  18 
SAC  +  rlFN-3,  23  15 
SAC  +  rTNF-c~  +  rlL-4  45  25 
SAC  +  rlFN-y  +  rlL-2  20  13 
Anti-#  16  12 
Anti-#  +  rlL-2  23  15 
Anti-/~  +  rlL-4  30  19 
Anti-#  +  rTNF-er  27  17 
Anti-/~  +  rlFN--y  19  14 
Expression of CDllc on tonsillar B cells cultured for 3 d with different 
stimuli (see Materials and Methods). Control represents the culture of 
B cells in complete medium. Specific  relative fluorescence  and percentage 
of positive cells were calculated as described in Materials and Methods. 
Data represent one experiment out of five different assays. 
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CD11/CD18  antigens  from  nonacti- 
vated (A) and activated (B) tonsillar B 
cells and from granulocytes (C). (B) B 
lymphocytes w~re subjected for 3 d to 
5 ng/ml of PMA. mI cell lysates were 
immunoprecipitated  with  control 
P3X63  mAb  (lane  1),  anti-CDlla 
TS1/11 mAb (lane,?), anti-CDllb Bear 
1 mAb (lane 3),  anti-CD11c  HC1/1 
mAb (lane 4), and anti-CD18  TS1/18 
mAb (lane 5). Reduced samples were 
subjected to a 7% SDS-PAGE. 
the release of a preformed pool from intracellular granules 
(reviewed in reference 3). To analyze the mechanisms of in- 
duction of CDllc/CD18 B cell surface expression, the steady- 
state  level of mRNA for both chains was  determined by 
Northern blot. While no mRNA for CDllc was detected 
on resting B cells, CDllc mRNA was evident at day 2 and 
reached a maximum by day 3 (Fig. 3 A). CD18 mRNA was 
already present on resting B cells (as expected from their LFA-1 
[CDlla/CD18] constitutive expression) and also showed an 
increase after PMA treatment (Fig. 3 B). The kinetics of the 
CDllc/CD18 appearance on the membrane and the mRNA 
levels for CDllc and CD18 suggest that the induced cell sur- 
face expression of CDllc/CD18 is not due to the release of 
a preformed pool but probably to the activation of the tran- 
scription of the CDllc gene and/or to an increase in the CDllc 
mRNA messenger stability. 
Monoclonal Antibodies Directed to CDllc Trigger Proliferative 
Responses on Activated Human B  Lymphocytes.  The expres- 
sion of CDllc on activated  B cells suggested that it could 
play a role in the regulation of B cell function at this stage. 
Since a number ofintegrins have been shown to trigger comito- 
genic signals on T cells (6-15), the functional effect of a wide 
panel of CDllc mAb was tested in proliferation assays. Highly 
purified tonsillar B cells were cultured with PMA to induce 
CD11c expression and were treated with CDllc mAb. Three 
CDllc mAbs induced comitogenic responses ranging from 
2.5- to 8-fold higher than PMA alone (Fig. 4). HC1/1 and 
KB23 mAbs triggered lower mitogenic  responses (2.5-4-fold) 
than BU15 mAb (4- to 8-fold). This CDllc-mediated prolifer- 
ative response was comparable to those observed with other 
stimuli or mitogenic combinations such as PMA plus anti- 
CD69 TP1/8 or anti-CD20 1F5 mAb and rlL-2 (or rIL-4) 
plus PMA (Fig. 4; and data not shown). The anti-CD21 HB5 
mAb or the anti-CD45 D3/9 mAb, included as controls, did 
not affect the response induced by PMA (Fig.  3;  and data 
not shown). Other anti-CDllc mAbs such as L29, KBg0, 
and S-HCL 3 failed to alter the PMA-induced proliferation 
(Fig.  4;  and data not shown). 
The CDllc mAb-mediated B cell proliferation was shown 
to be:  (a) dose dependent for both mAb and phorbol ester 
(Fig. 5); (b) isotype independent, as concluded from the Ig 
dass of the mAb tested; and (c) Fc independent, since similar 
proliferation effects could be obtained with the F(ab')2 frag- 
ments of HC1/1 mAb (Pigs.  4 and 5).  In addition, cross- 
Figure 3.  Induction of CDllc/CD18 
mRNA levels in purified human tonsil- 
lar B lymphocytes. (.,1) CDllc mRNA 
levels in B lymphocytes either nonacti- 
rated  (lane  I),  or  PMA-activated  (5 
ng/ml) for 24 h (hne 2), 48 h (lane 3), 
and 72 h (lane 4). mRNA from the my- 
domonocytic U937 ceU line (lane 5) and 
PMA-treated (5 ng/ml) U937 calls (lane 
6) were included  as controls.  (B) 82 
mRNA levels in purified human ton- 
sillar B cells either  nonactivated  (lane 
1) or activated with PMA (5 ng/ral) for 
24, 48, or72h 0aries 2, 3, and4, respec- 
tively). 3-d PMA-activated (5 ng/ml) 
U937 mRNA was loaded in lane 5. In 
every case, a similar amount of RNA 
(10 ~g) was loaded,  as controlled  by 
ethidium  bromide staining of the gel. 
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Figure 4.  B cell proliferation  induced by anti-CD11c, 
anti-CD20, anti-CD69, and anti-CD21 mAbs. mAbs were 
added at day 0 in the absence Oqlled bars) or presence (hatched 
bars) of PMA (3 ng/ml). The [3H]TdR. uptake was mea- 
sured at day 3. HCI/1, BU15, L29, and F(ab')2  fragments 
of HC1/1,  1F5, TPl/8, and HB5 mAbs were added at 
2 #g/m1. Anti-CDllc KB23 and KBg0 mAbs were added 
as a 1:600  asdtes dilution. 
linking of CDllc. mAb did not seem to be necessary since 
either  soluble or crosslinked  HC1/1  mAb  elicited  similar 
proliferative  responses  (data not shown), in contrast  with 
results  obtained with other  B2  integrin mAbs  on T  cell 
proliferation  (12). 
This integrin-mediated  B  cell  proliferation  was CDllc 
specific since CDlla TS1/11 and CDllb Bear 1 mAbs failed 
to alter B cell proliferation,  although a wider panel of mAbs 
are currently  been testing (see below).  The CD18 TS1/18 
mAb consistently induced small increases of [3H]TdR incor- 
poration ranging from 1- to  1.5-fold (data not shown). 
Finally, to ascertain whether the continuous presence of 
a protein kinase C (PKC) activator was necessary for the trig- 
gering of the mitogenic responses  through CD11c,  B cells 
were activated with PDB for 2 d. After removal of the phorbol 
ester, the CDllc expression remained constant at days 3 and 
4 (data not shown), and B cell proliferation  could be trig- 
gered with CDllc mAb (Table 2). Therefore, the continuous 
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Figure  5.  B  cell proliferation  induced by intact and 
F(ab')2 fragments of anti-CDllc mAb. Purified tonsiUar 
B cells were cultured with PMA with either intact (solid 
lines)  or F(ab')2 fragments (dotted lines)  of HC1/1  mAb 
at different doses.  (O) No mAb; (O and e) 0.1/~g/ml; 
(l-1 and I)  1/~g/ml;  (A and A) 5/~g/ml.  "Cells cul- 
tured with complete medium alone. Table  2.  B  Cell Proliferation through CDllc in the Absence 
of Concomitant PKC Activators 
Not washed"  Washed* 
-HC1/1  + HC1/1  -HC1/1  +HC1/1 
Control  0.25_+ 0.15  0.12_+ 0.05  0.35_+ 0.21  0.28_+ 0.12 
PDB  5.31_+ 0.91  14.35_+  1.63  0.65_+ 0.18  7.82 +_ 1.32 
PMA  5.25 +_ 1.25  17.25  +_ 2.01  4.60 _+ 1.35  12.32 +_ 2.13 
Purified tonsillar  B cells were activated with PDB (10 ng/ml) or PMA 
(5 ng/ml). [3H]TdR incorporation  (cpm  x  10 -3) was measured at day 
4.  [3H]TdR uptake  was  calculated  as  mean  of triplicate  values.  Data 
represent  one experiment out of five different  assays. 
* At 48 h,  2 #g/ml of HC1/1  mAb was  added. 
* In  the washed  condition,  after  2 d,  cells were gently washed  with 
RPMI 1640, resuspended in complete medium, and, upon overnight in- 
cubation,  2/zg/ml of HC1/1 mAb was  added. 
of CD11c HC1/1 and CD18 TS1/18 mAbs in B call attach- 
ment to FN38 were observed. Likewise, anti-CD49d (VLA- 
c~4) HP2/1 mAb did not inhibit B cell binding to FG (data 
not  shown).  Therefore,  CDllc/CD18  integrin  acts  as  a 
receptor for FG on human B cells in the absence of CDllb 
surface expression. 
A perfect correlation was observed between the comito- 
genie activity of CDllc mAbs and their inhibitory effect on 
B cell attachment to FG: HC1/1, KB23, and BU15 were able 
to trigger B cell proliferation and to inhibit the call binding 
to FG. This fact led us to explore whether FG had any effect, 
either mitogenic or inhibitory, on the CDllc mAb-medi- 
ated B cell proliferation. As shown in Table 3, FG inhibited 
the proliferation induced by CDllc mAbs.  The partial in- 
hibitory effect of FG probably reflects the inaccessibility of 
CDllc to the added mAbs caused by the redistribution of 
the antigen induced by the surface-bound ligand, a fact al- 
ready observed for Mac-1  (45). 
presence of a PKC activator is not required for the comito- 
genic signals  delivered through CDllc. 
B  Cell Activation Induces CDllc-mediated Cell Attachment 
to Fibrinogen. Fibrinogen Reverts B Cell Proliferation Triggered 
by CD11c mAt~  Very recently, it has been reported that ac- 
tivated neutrophils interact with fibrinogen (F-G) through both 
Mac-1 (42, 43) and p150,95 (44). To analyze the functional ad- 
hesive capacities of CD11c/CD18 in the absence of CDllb ex- 
pression, FG binding assays were performed on either resting 
and activated B cells.  As shown in Fig.  6,  PMA-treated B 
cells, but not nonactivated B cells, were able to interact with 
FG. The specific involvement of CDllc/CD18 in the B cell 
attachment to FG was demonstrated by the ability of CDllc 
and CD18 mAbs to block the binding (Fig. 6). Adhesiveness 
to collagen (COL) and to a fibronectin fragment (FN38) con- 
taining the domain recognized by VLA-4 (CD49d/CD29) 
integrin was included as control (32).  No inhibitory effects 
Discussion 
The results reported here reveal that CDllc/CD18 can be 
induced on purified human B cells upon activation with sev- 
eral stimuli such as phorbol esters or either SAC or anti-# 
antibodies  combined  with  cytokines.  In  addition,  the 
CDllc/CD18 integrin is involved in both B cell activation 
and adhesion, since mAbs against this molecule trigger B 
cell proliferation and block cell binding to FG. 
The coexpression of CD11b and CD11c is known to be 
restricted to granulocytes, monocytes, and NK cells (16, 17). 
CDllc expression has been also demonstrated on dendritic 
cells (18, 19) and on some transformed T lymphocytes (20). 
Among the B cell lineage, the expression of CDllc has been 
reported in the HCL cells and in some B-CLL (21, 22, 46), 
which are also CD11b + and CD5 + (22).  Recently, a small 
CD5 +  CDllc +  B  cell  subset  on  peripheral  blood  from 
normal donors has been detected and proposed as the normal 
counterpart of B-CLL cells (46). 
f- 
alAb 
PROTEIN 
HP2~  ~  HCI~  BUT5  K023  L29  gBgo  SHCL3  TS1/~  TSl/n  OgM1  ORMI0 
CD49d  CDl1r  CDlll  CDlto  CDnb 
COL  FN~  FG  COL  FN38  FG 
RESTING  ACTIVATED 
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Figure 6.  Binding of either nonac- 
tivated or 3-d activated tonsillat B ceils 
to plates coated with type I collagen, 
a  38-kD  proteolytic  fragment  of 
fibronectin  (FN38),  or FG.  B cells 
were activated with PMA (5 ng/ml) 
and adhesion assays were performed 
as described in Materials and Methods. 
mAb concentrations:  HC1/1, BU15, 
L29, TS1/18, and TS1/11 were used 
at 5/zg/ml; HP2/1 was used as cul- 
ture  supernatant  at  a  25%  final 
volume concentration;  KB23, KB90, 
OKM1,  and  OKM10  as  a  1/400 
ascites dilution; and  S HCL-3  at  a 
1/200  ascites dilution.  The  figure 
represents the average of five different 
experiments. Table  3.  Fibrinogen Blocks the CD11c mAb-mediated B Cell 
Proliferation 
-  FG  +  FG 
Medium  0.67  _+ 0.32  0.71  +  0.34 
HC1/1 mAb  0.55  -+ 0.24  0.68  _+ 0.18 
PMA  7.78  _+ 0.87  6.88  _+  1.13 
PMA  +  HC1/1 mAb  26.47  _+  1.81  14.45  _+  1.92 
Effect of FG in CDllc mAb-mediated  B cell proliferation. FG was coat- 
ed to plates at 20 gg/ml (100 gl/well) overnight at 4~  Plates were 
gently washed and tonsillar B cells were added and activated with PMA 
(2 ng/ml) and/or HC1/1 mAb (5/ig/ml). Each condition was performed 
by triplicate. [3H]TdR uptake was measured at  day 3.  These data 
represent one experiment out of four different assays. 
The expression of CDllc by leukemic B cells  suggested 
that  its expression could be associated with cell activation 
processes. This fact has been confirmed by our finding of in- 
duction of CDllc expression during B cell activation.  It is 
worth  noting  the lack of induction  of CDllb,  as opposed 
to its expression by B-CLL cells, suggesting a different regu- 
lation in the expression of both CDllb and CDllc, on normal 
and transformed  human  B cells. 
After activation, B cells undergo a number of phenotypic 
changes in the expression of their surface molecules that are 
closely related to the activation signal (23-32). For example, 
only phorbol esters induce CD5 expression on B cells, whereas 
other stimuli such as anti-g Ab and several cytokines fail to 
induce this B cell activation antigen (29). Our data demon- 
strate that CDllc expression is mainly induced after phorbol 
ester treatment, although it could also be obtained upon treat- 
ment with the more physiological B cell activation  agents 
SAC or anti-# Ab in combination with cytokines. The slow 
pattern of induction of CDllc on B cells resembles that ob- 
served on U937 and HL60 myelomonocytic cell lines after 
PMA treatment (47) and may reflect the existence of phorbol 
ester responsive dements on the promoter region of the CDllc 
gene (A.L.  Corbi,  unpublished  observations). 
Although originally integrins were believed to participate 
only in adhesion processes, recent reports demonstrate that 
they are also involved in cell activation.  Thus, comitogenic 
signals can be triggered through VLA-4, VLA-5, and VLA- 
6 on activated T  cells  (6-9),  and the expression of certain 
matrix-degrading protease genes (48) and transcription factors 
(49) is induced through  VLA-5.  Moreover, other noninte- 
grin adhesion molecules such as CD44 homing receptor and 
the CD2/LFA-3 pair have been also implicated in cell activa- 
tion (50-53).  Our data constitutes the first evidence about 
the implication of integrins  in B cell proliferation and fur- 
ther strengthens  the link between adhesion and cell activa- 
tion.  Other/32  integrins  have been also implicated in cell 
activation. Thus, CDllb mAbs have been reported to induce 
macrophage  activation  (54),  and  both  CDlla  and  CD18 
subunits are also involved in T  cell activation (10-15).  On 
B cells, LFA-1 mAbs have been reported to inhibit T cell-de- 
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pendent  B  cell proliferation  and  differentiation,  although 
CDlla mAbs have no effect on purified B cells (55-58). These 
data correlate with our results about the inefficiency of the 
anti-CDlla TS1/ll mAbs to alter the proliferative response 
induced by PMA.  The lack of effect of LFA-1 mAbs on B 
cell proliferation  as compared to that  observed for T  cells 
could reflect a different role of this integrin in T  and B cell 
activation processes. At present,  we are analyzing  a wider 
panel of CDlla mAbs to further clarify the LFA-1 involve- 
ment  on B cell activation. 
The comitogenic effect of CDllc mAbs does not seem to 
be mediated via PKC activation. Moreover, none of the mito- 
genic anti-CDllc mAbs induced any change in the intracel- 
lular Ca  2+ levels of activated CDllc + B cells, even when a 
crosslinking agent was added (A.A. Postigo, unpublished ob- 
servations). Furthermore, the mitogenic response elicited by 
CDllc mAbs did not require the continuous presence of PKC 
activators,  suggesting that  CDllc cell surface expression is 
enough to allow B cell proliferation via CDllc. To the best 
of our knowledge, no data exist about the involvement of 
CDllc/CD18  on cell proliferation,  and further  research  is 
required to ascertain whether this activation effect could also 
be observed on other CDllc-expressing cell types. The differ- 
ence in the proliferative response elicited by the CDllc mAbs 
assayed here suggests the existence of different functional do- 
mains on CDllc.  It would be of interest to correlate these 
functional domains with those involved in the binding  of 
CDllc/CD18  to its endothelial  ligand  (59). 
Among the/32 integrins,  the functional role of CDllc is 
the least known, and some controversy exists about its ligand- 
binding abilities.  Thus, while some studies have implicated 
CDllc/CD18 in the cytotoxicity mediated by certain T cell 
dones (20), others have questioned this involvement (17). iC3b 
has also been postulated to be a ligand  for CDllc  (60) al- 
though CDllc/CD18-transfected  COS cells fail to bind to 
this complement factor (3). CDllc/CD18 has also been in- 
volved in  granulocyte  binding  to  endothelium,  although 
playing only an ancillary role in respect to that of LFA-1 and 
Mac-1 (61, 62), and contradictory evidence about the partici- 
pation of CD11c/CD18 in monocyte adhesion to endothelium 
has been reported (63, 64). Our results indicate that CD11c/ 
CD18 is a receptor for FG on B cells,  a fact that has been 
recently reported on TNF-activated neutrophils (44). So far, 
CDllc/CD18 is the only/32 integrin without an identified 
endothelial ligand,  although the existence of such as ligand 
has been demonstrated with purified CDllc protein (59). The 
other two/32 integrins, LFA-1 and Mac-l, share intercellular 
adhesion molecule 1 (ICAM-1) as a counter-receptor on en- 
dothelium,  through recognition of different domains of the 
molecule  (65,  66).  The  FG-binding  ability of Mac-1  and 
p150,95 follows the same scheme: both are able to interact 
with the same ligand, although recognizing distinct domains 
(42, 44). Given the structural  similarity among them,  it is 
tempting to speculate that the three leukocyte integrins can 
recognize a common  set of ligands. 
The ability of the mitogenic CDllc mAbs to block B cell 
binding to FG suggested that FG could be involved in B cell 
activation. However, FG did not trigger mitogenic responses although it was able to inhibit CDllc mAb-mediated B cell 
proliferation. This fact could be explained because  FG may 
bind to a CDllc region close, but not identical, to that defined 
by the mitogenic CDllc mAbs. 
In summary, our data constitute the first evidence for the 
induction of CD11c/CD18 on nontransformed B cells and 
its involvement on cell activation. The functional capability 
of certain CDllc mAbs to trigger B cell proliferation and 
to inhibit FG binding indicate that this integrin plays a role 
in  the  regulation of both  B  cell  activation and adhesion 
processes, mAbs directed to CD11c could exert their mito- 
genic effects by mimicking the interaction of CDllc with 
its natural ligand. Whether iC3b or the putative endothelial 
ligand are able to induce proliferative  responses on CD11c § 
B cells remains to be explored. To that effect, purified en- 
dothelial ICAM-1 molecule is able to trigger mitogenic re- 
sponses by binding to LFA-1 on T cells (15), and the prolifer- 
ative  effects  of other  complement  factors  on  normal  B 
lymphocytes and B  cell  lines  have been  also  documented 
(67-71).  The  triggering  of B  cell  proliferative  responses 
through CDllc/CD18 by iC3b and endothelium is currently 
under study in our laboratory. 
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